Form 4: Pfizer SVP & Controller Jennifer B. Damico Reports Transactions in Company Stock

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the acquisition and disposal of company stock, including restricted stock units and stock appreciation rights, according to a Form 4 filing.

Summary

• On February 27, 2025, Jennifer B. Damico disposed of 749 shares of Pfizer common stock at $26.10 to satisfy tax obligations upon the vesting of restricted stock units.
• On March 4, 2025, she acquired 5,583 shares of common stock through the grant of restricted stock units.
• Also on March 4, 2025, she disposed of 2,500 shares of common stock at $25.93.
• She was also granted 47,511 stock appreciation rights on March 4, 2025, exercisable on March 4, 2030, settled in shares of Pfizer common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to executive compensation. The acquisition of shares through restricted stock units and stock appreciation rights is a positive sign, but the sale of shares is a neutral event.

Positives

• The grant of restricted stock units and stock appreciation rights suggests continued confidence in the company's future performance.

Negatives

• The sale of 2,500 shares on March 4, 2025, could be interpreted negatively, although it's a relatively small portion of her holdings.

Risks

• Vesting requirements for restricted stock units and stock appreciation rights could be affected by changes in company performance or employment status.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of restricted stock units and the granting of stock appreciation rights suggest an expectation of continued employment and company performance.

Industry Context

Insider transactions are common in publicly traded companies and are closely monitored by regulators and investors for insights into management's view of the company's prospects. This filing is a routine disclosure of such transactions.

Comparison to Industry Standards

• Insider transactions are a normal part of executive compensation at large pharmaceutical companies like Johnson & Johnson (JNJ), Merck (MRK), and AbbVie (ABBV).
• The structure of restricted stock units and stock appreciation rights is a common incentive mechanism used across the industry to align executive interests with shareholder value.
• The vesting schedules and terms of these instruments are generally comparable to those offered by peer companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock or signaling management's view of the stock's value.

Key Dates